Literature DB >> 6818656

Clindamycin: a review of fifteen years of experience.

V K Dhawan, H Thadepalli.   

Abstract

Clindamycin, the 7(S)-chloro-7-deoxy derivative of lincomycin, has stood the test of time in the treatment of anaerobic infections. Clindamycin inhibits protein synthesis by acting on the 50S ribosomal subunits of bacteria. The colitis resulting from the use of clindamycin has been extensively studied and is now easily manageable. Although newer antibiotics active against anaerobes are available, clindamycin remains a reliable and well-tested antibiotic for use in anaerobic infections.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6818656     DOI： 10.1093/clinids/4.6.1133

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


  18 in total

Review 1.  Clindamycin as an antimalarial drug: review of clinical trials.

Authors:  Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

3.  Characterization of a Novel lsa(E)- and lnu(B)-Carrying Structure Located in the Chromosome of a Staphylococcus aureus Sequence Type 398 Strain.

Authors:  S Sarrou; A Liakopoulos; K Tsoumani; E Sagri; K D Mathiopoulos; L S Tzouvelekis; V Miriagou; E Petinaki
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

4.  linG, a new integron-associated gene cassette encoding a lincosamide nucleotidyltransferase.

Authors:  Renee S Levings; Ruth M Hall; Diane Lightfoot; Steven P Djordjevic
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.

Authors:  Jemila C Kester; Douglas K Brubaker; Jason Velazquez; Charles Wright; Douglas A Lauffenburger; Linda G Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci.

Authors:  M Arditi; R Yogev
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

7.  Evaluation of the 10-micrograms clindamycin disk for susceptibility testing of anaerobes by the aerobically incubated thioglycolate broth disk method.

Authors:  K L Toohey; T A Kurzynski; R F Schell; R J Birk; R J Zabransky
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

8.  Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  M M París; S Shelton; M Trujillo; S M Hickey; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

9.  A new resistance gene, linB, conferring resistance to lincosamides by nucleotidylation in Enterococcus faecium HM1025.

Authors:  B Bozdogan; L Berrezouga; M S Kuo; D A Yurek; K A Farley; B J Stockman; R Leclercq
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

10.  Effects of clindamycin and metronidazole on the intestinal colonization and translocation of enterococci in mice.

Authors:  C L Wells; R P Jechorek; M A Maddaus; R L Simmons
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.